Dioxazaborocane derivative

The 1,3,6,2-dioxazaborocane derivatives address the limitations of existing boronic acid adducts by providing a glucose-responsive mechanism for controlled drug release through pH modulation and polymer incorporation, enhancing the stability and responsiveness of drug delivery systems.

WO2024232325A1PCT designated stage expired Publication Date: 2024-11-14INSTITUTE OF SCIENCE TOKYO +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/016791
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-08
Filing Date
2024-05-01
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current boronic acid adducts, such as SHABA, IB, OB, and HB, exhibit stability under physiological conditions but fail to dissociate in response to high glucose concentrations, limiting their effectiveness in glucose-responsive drug delivery systems.

Method used

The development of 1,3,6,2-dioxazaborocane (DOAB) derivatives, which undergo a dissociation mechanism in response to glucose, allowing for controlled drug release through pH modulation and incorporation into polymer networks as dynamic covalent cross-linking units.

Benefits of technology

DOAB derivatives demonstrate adjustable binding and hydrolysis rates, enabling glucose-responsive drug delivery and stable incorporation into polymers, facilitating controlled drug release and reversible polymer networks.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024016791_14112024_PF_FP_ABST
    Figure JP2024016791_14112024_PF_FP_ABST
Patent Text Reader

Abstract

The purpose of the present invention is to provide a boron adduct, which is capable of dissociating in the presence of a high glucose concentration and subsequently releasing a covalently bound drug, in order to establish a glucose-responsive drug delivery system. 1,3,6,2-dioxazaborocane (DOAB) is a neutral boronic acid adduct formed by a condensation reaction between boronic acid (BA) and a diethanolamine (DEA) derivative. The boronic acid and diethanolamine derivative exhibit an N-B dative bond that thermodynamically stabilizes the adduct. The values of a binding constant (Ka ≈ 100–102 M-1) and a hydrolysis rate constant (kr ≈ 10-3–10-6 s-1) in an aqueous solution having a pH of 7.4 can be adjusted in a wide range.
Need to check novelty before this filing date? Find Prior Art

Description

Dioxazaborocane derivatives

[0001] The present invention relates to dioxazaborocane (DOAB) derivatives and methods for their preparation. More specifically, the present invention relates to the chemical structures of 1,3,6,2-dioxazaborocanes, their stability and hydrolysis rates in aqueous solutions at different pH values, control of glucose responsiveness, and incorporation into biomolecules and polymers.

[0002] Classical boronate esters of aliphatic 1,2- or 1,3-diols generally suffer from thermodynamic instability in aqueous environments. Over the past two decades, new boronate adducts have been developed, significantly improving their stability under physiological conditions. Frequently used boronate adducts include salicylhydroxamic acid-boronic acid (SHABA), iminoboronate (IB), oximeboronate (OB), and hydrazoneboronate (HB) (Figure 1). These compounds are stable at neutral pH and can be hydrolyzed under acidic conditions. Therefore, pH-responsive drug delivery systems have been developed by incorporating these moieties into enzymes or polymers.

[0003] WO2003105860A1 (Patent Document 1) discloses the pharmaceutical use of boronic acids and esters thereof. The compounds disclosed therein are inhibitors of hormone-sensitive lipase and are believed to be useful in the treatment and / or prevention of various medical disorders in which a decrease in hormone-sensitive lipase activity is desired.

[0004] WO2006071586A1 (Patent Document 2) discloses boron compounds as stabilizers for photothermography. The materials disclosed in this document contain one or more boron compounds as stabilizers in an amount of at least 0.001 g / m. 2 These boron compounds have the moiety XB(OL)-Z.

[0005] WO2010018211A1 (Patent Document 3) discloses cyclopropyl- and cyclobutyl-dioxazaborocane or dioxazaborecane derivatives, which can be used in particular to store or as precursors of the corresponding boronic acid derivatives, especially in Suzuki coupling reactions.

[0006] WO2003105860A1WO2006071586A1WO2010018211A1

[0007] SHABA (K a ≒10 5 M -1 ), OB (K a ≒10 5 ~10 7 M -1 ) and HB(K a ≒10 4 ~10 6 M -1 ) exhibits high stability in aqueous solution under physiological conditions (K a represents the binding constant). However, they cannot react with glucose via a dissociation mechanism. The interaction between glucose and boronic acid (BA) is much weaker (K a ≒10 1 ~10 2 M -1 ), competitive binding of glucose is difficult. IB, like the glucose-BA complex, exhibits weak binding strength, but the interaction with glucose is a non-dissociative process, so the boron adduct does not dissociate after glucose binding.

[0008] To establish a glucose-responsive drug delivery system, it is necessary that the boron adduct be able to dissociate in the presence of high glucose concentrations, subsequently releasing the covalently attached drug.

[0009] 1,3,6,2-Dioxazaborocane (DOAB) (I) is a neutral boronic acid adduct formed by the condensation reaction between boronic acid (BA) (II) and diethanolamine (DEA) (III) derivatives. They exhibit an N-B coordinate bond that thermodynamically stabilizes the adduct. The binding constant (K) in aqueous solution at pH 7.4 is a ≒100 ~10 2 M -1 ) and the hydrolysis rate constant (k r ≒10 -3 ~10 -6 s -1 ) can be adjusted within a wide range.

[0010] DOAB (I) can interact with glucose via a dissociation mechanism that leads to the glucose-BA derivative (IV). Furthermore, we demonstrate that DOAB groups can be incorporated into polymer networks as dynamic covalent cross-linking units while maintaining the reversibility of the equilibrium reaction.

[0011] A schematic diagram of the hydrolysis reaction of substituted 1,3,6,2-dioxazaborocane (I) to boronic acid (II) and diethanolamine (III), and the exchange reaction to glucose-BA (IV) are shown below.

[0012]

[0013] In the above formula, for example, A1 and A2 each independently represent either H or a methyl group; Y represents either a CH group or an N atom; R1 each independently represent either H, an electron-donating group (e.g., NMe2, OH, OMe, Me, etc.) or an electron-withdrawing group (e.g., CF3, NO2, CN, Br, CONH, etc.); R2 represents either H or an alkyl group; and the arrow pointing from N to B represents a coordinate bond.

[0014] That is, the present invention provides the following: [Item 1] A compound represented by formula I: (I) In the formula, A 1a represents a H atom or a methyl group, and A 1b represents a H atom or a methyl group, and A 1c represents a H atom or a methyl group, and A 1d represents an H atom or a methyl group, where A 1a , A 1b , A 1c , A 1d At least one of A is a methyl group, 2arepresents a H atom or a methyl group, and A 2b represents a H atom or a methyl group, and A 2c represents a H atom or a methyl group, and A 2drepresents an H atom or a methyl group; each Y independently represents a substituted or unsubstituted —CH— or N atom; there may be 1, 2, 3, 4, or 5 R1's, each independently representing an H atom, an F atom, an electron-donating group (e.g., NMe2, OH, OMe, Me, etc.), an electron-withdrawing group (e.g., CF3, NO2, CN, Br, CONH, etc.), a linker, or a bond; R2 represents an H atom, a substituted or unsubstituted alkyl group, a linker, or a bond; and the arrow pointing from N to B represents a coordinate bond. [Item 2] The following group: 2-(3-Fluorophenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3-(Trifluoromethyl)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-Cyanophenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-Nitrophenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-(trifluoromethyl)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3-(Trifluoromethyl)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-Tolyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-Methoxyphenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-(dimethylamino)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane (2-(4-(Dimethylamino)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane), 2-(3,5-Difluorophenyl)-6-methyl-[1,3,6,2]dioxazaborocane), 2-(3,5-Di(trifluoromethyl)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane), 2-(3-Fluoro-4-((2-acrylamidoethyl)carbamoyl)-phenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3,4,5-Trifluorophenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3-Pyridyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(2-Fluoro-3-pyridyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-Carboxy-3-pyridyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-pyridyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3-Pyridyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-Phenyl-4R,8R-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane8R-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane), 2-Phenyl-4S,8S-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane), 2-Phenyl-rac-(4,8)-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane), 2-Phenyl-rac-(4,8)-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane), 2-(3-Fluorophenyl)-rac-(4,8)-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3,5-Difluorophenyl)-rac-(4,8)-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3-Fluoro-4-((2-acrylamidoethyl)carbamoyl)-phenyl)-rac-(4,8)-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane, 2-Phenyl-4,4',6-trimethyl-[1,3,6,2]dioxazaborocane, 2-Phenyl-4,4',6,8,8'-pentamethyl-[1,3,6,2]dioxazaborocane, 2-Phenyl-4,4',6,8,8'-pentamethyl-[1,3,6,2]dioxazaborocane, 2-Phenyl-4,4',6,7,8'-pentamethyl-[1,3,6,2]dioxazaborocane2] dioxazaborocane) or a derivative thereof. [Item 3] The compound according to Item 1, wherein any one of R1 is linked to a polymer (e.g., BA-DMA copolymer), a functional peptide (insulin), or a drug (including, for example, a protein). [Item 4] The compound according to Item 1, wherein R2 is linked to a polymer (e.g., DEA-DMA copolymer). [Item 5] A method for adjusting the binding / dissociation reaction shown below, comprising: (In the formula, A 1a represents a H atom or a methyl group, and A 1b represents a H atom or a methyl group, and A 1c represents a H atom or a methyl group, and A 1d represents an H atom or a methyl group, where A 1a , A 1b , A 1c , A 1d At least one of A is a methyl group, 2a represents a H atom or a methyl group, and A 2b represents a H atom or a methyl group, and A 2c represents a H atom or a methyl group, and A 2d represents an H atom or a methyl group, each Y independently represents a substituted or unsubstituted -CH- or N atom, there may be 1, 2, 3, 4, or 5 R1's, each independently representing an H atom, an F atom, an electron-donating group (e.g., NMe2, OH, OMe, Me, etc.), an electron-withdrawing group (e.g., CF3, NO2, CN, Br, CONH, etc.), a linker, or a bond, R2 represents an H atom, a substituted or unsubstituted alkyl group, a linker, or a bond, and the arrow pointing from N to B represents a coordinate bond.) A method characterized by changing the pH of the solution. [Item 6] The method according to Item 5, wherein the dissociation reaction is promoted by increasing or decreasing the pH away from the optimum pH for the bond.

[0015] The greater stability of (I) at pH 7.4 can be achieved by a more acidic boronic acid (R1 modification), methylation of the bicyclic ring (A1 modification), and N-alkyl substitution (R2 modification). The glucose-sensitive dissociation of (I) at pH 7.4 can be achieved by the addition of electron-withdrawing groups to the phenyl ring (R1 modification) and methylation of the bicyclic ring (A1 modification). Indeed, DOAB remains stable at low glucose concentrations (<6 mM) and begins to dissociate with increasing glucose concentrations (6-20 mM).

[0016] The incorporation of DOAB units into polymeric networks can be achieved by N-substitution (R2 modification) and phenyl substitution (R1 modification).

[0017] Schematic diagram of frequently used boronic acid adducts and their limited glucose interaction capacity. Binding strengths (binding constants K) of various R1-, R2-, and A1-modified DOAB adducts (I) a ) vs. pH value. Unless otherwise stated, R1 = H; R2 = Me; Y = CH; A1 / A2 = H. [DOAB] = 20 mM; solvent = H2O / D2O 9:1. The binding strength (binding constant K a ) vs. pH value. Unless otherwise stated, R1 = H; R2 = Me; Y = CH; A1 / A2 = H. [DOAB] = 20 mM; solvent = H2O / D2O 9:1. The binding strength (binding constant K a ) vs. pH value. Unless otherwise stated, R1 = H; R2 = Me; Y = CH; A1 / A2 = H. [DOAB] = 20 mM; solvent = H2O / D2O 9:1. The DOAB concentration (Figure 3A) and apparent binding constant (K) of the A1-modified DOAB adduct at different time intervals were plotted. a,t , , Figure 3B). Other substituents: R1 = H; R2 = Me; Y = CH; A2 = H. [DOAB] = 5 mM; solvent = 0.1 M phosphate buffer (pH 7.4) with a 9:1 H2O / D2O ratio. The DOAB concentration (Figure 3A) and apparent binding constant (K) of the A1-modified DOAB adduct at different time intervals were plotted. a,t, , Figure 3B). Other substituents: R1 = H; R2 = Me; Y = CH; A2 = H. [DOAB] = 5 mM; solvent = 0.1 M phosphate buffer (pH 7.4) with HO / DO 9:1. Dissociation of A1- and R1-modified DOAB adducts dependent on glucose concentration. Figure 4A shows a highly glucose-responsive DOAB (R1 = 3-F, R1 = 4-CONH-Et-AAm; A1 = Me / H). Figure 4B shows a less glucose-responsive DOAB (R1 = H; A1 = Me / H). Other substituents: R2 = Me; Y = CH; A2 = H. [DOAB] = 20 mM; solvent = HO / DO 9:1. Dissociation of A1- and R1-modified DOAB adducts dependent on glucose concentration. Figure 4A shows a highly glucose-responsive DOAB (R1 = 3-F, R1 = 4-CONH-Et-AAm; A1 = Me / H). Figure 4B shows a less glucose-responsive DOAB (R1 = H; A1 = Me / H). Other substituents: R2 = Me; Y = CH; A2 = H. [DOAB] = 20 mM; solvent = H2O / D2O 9:1. Schematic of DOAB crosslinked hydrogel. Dynamic behavior of the hydrogel at different pH values ​​visualized macroscopically by the sol-gel transition. Schematic of the R1-modified DOAB studied. Binding constant K a The relationship between the binding constant K and the pH value is shown. a The relationship between the binding constant K and the pH value is shown. a The relationship between the pH and the DOAB concentration is shown. Schematic diagram of the A1-modified DOAB studied. The DOAB concentration at different time intervals is shown. The dashed lines are the fitting results of the kinetic model. Schematic diagram showing the possible interaction of DOAB with glucose via binding or dissociation mechanisms. Glucose-BA (K a,glucose ) and DOAB(k a,DOAB ) binding constant equation for the equilibrium reaction. High glucose response (K a,DOAB ≦K a,glucose Schematic diagram of the investigated R1 and A1 modified DOABs showing the effect of glucose on the ATP-dependent ATP synthesis. 11 The B NMR spectrum shows the ratio of DOAB, glucose-BA, and BA. Low glucose response (K a,DOAB >Ka,glucose Schematic diagram of A1 modified DOAB showing the change in glucose concentration. 11 1. B NMR spectrum. 2. Ratios of DOAB, Glucose-BA, and BA are shown. 3. Schematic diagram of monomer and polymer. 4. Schematic diagram of cross-linked polymer formation and partial hydrolysis with acid or base. 5. Dynamic behavior of cross-linked polymer at different pH values ​​visualized macroscopically by sol-gel transition. 6. At different time intervals after mixing the polymer solutions. 11 The results of B NMR are shown.

[0018] One aspect of the present disclosure relates to compounds represented by Formula I: (I) (wherein, A 1a represents a H atom or a methyl group, and A 1b represents a H atom or a methyl group, and A 1c represents a H atom or a methyl group, and A 1d represents an H atom or a methyl group, where A 1a , A 1b , A 1c , A 1d At least one of A is a methyl group, 2a represents a H atom or a methyl group, and A 2b represents a H atom or a methyl group, and A 2c represents a H atom or a methyl group, and A 2d represents an H atom or a methyl group; each Y independently represents a substituted or unsubstituted -CH- or N atom; there may be 1, 2, 3, 4, or 5 R1's, each independently representing an H atom, an F atom, an electron-donating group (e.g., NMe2, OH, OMe, Me, etc.), an electron-withdrawing group (e.g., CF3, NO2, CN, Br, CONH, etc.), a linker, or a bond; R2 represents an H atom, a substituted or unsubstituted alkyl group, a linker, or a bond; and the arrow pointing from N to B represents a coordinate bond.

[0019] In some aspects of the present disclosure, A 1a , A 1b , A 1c , A 1dAt least one, two, or three of the groups are methyl groups, and the rest are H.

[0020] In some aspects of the present disclosure, A 1a , A 1b , A 1c , A 1d One, two, or three of the groups are methyl groups, and the rest are H.

[0021] In some aspects of the present disclosure, A 1a and A 1b One of the groups is H and the other is a methyl group, and A 1c and A 1d One of them is H and the other is a methyl group.

[0022] In some aspects of the present disclosure, A 1a , A 1b , A 1c , A 1d All of the groups are methyl groups.

[0023] In some aspects of the present disclosure, A 2a , A 2b , A 2c , A 2d All of them are H.

[0024] In some aspects of the present disclosure, A 2a , A 2b , A 2c , A 2d At least one, two, or three of the groups are methyl groups, and the rest are H.

[0025] In some aspects of the present disclosure, A 2a , A 2b , A 2c , A 2d One, two, or three of the groups are methyl groups, and the rest are H.

[0026] In some aspects of the present disclosure, A 2a , A 2b , A 2c , A 2d All of the groups are methyl groups.

[0027] In some embodiments of the present disclosure, R1 can be F, CF3, CN, NO2, CH3, OCH3, N(CH3)2, (CF3)2, CONH-Et-AAm, or COOH.

[0028] In some embodiments of the present disclosure, R1 can be F at position 3, CF3 at position 3, CN at position 4, NO2 at position 4, CH3 at position 4, OCH3 at position 4, N(CH3)2 at position 4, F at positions 3 and 5, (CF3) at positions 3 and 5, F at position 3 and CONH-Et-AAm at position 4, F at positions 3, 4 and 5, F at position 2, or COOH at position 4.

[0029] In some aspects of the present disclosure, the bond is a single bond.

[0030] In some embodiments of the present disclosure, the linker is a substituted or unsubstituted alkyl. The linker can include, for example, a non-ester-containing linker moiety and an ester-containing linker moiety. In some embodiments, the linker is a non-ester-containing linker. Suitable non-ester-containing linkers include, but are not limited to, amide (-C(O)NH-), amino (-NR-), carbonyl (-C(O)-), carbamate (-NHC(O)O-), urea (-NHC(O)NH-), disulfide (-SS-), ether (-0-), succinyl (-(0)CCH2CH2C(0)-), succinamidyl (-NHC(0)CH2CH2C(0)NH-), ether, disulfide, and combinations thereof (e.g., a linker containing both a carbamate linker moiety and an amide linker moiety). In some embodiments, a carbamate linker can be used to attach a DOAB derivative to a polymer, etc. In other embodiments, an ester-containing linker moiety can be used to attach the DOAB derivative to a polymer or the like. Suitable ester-containing linkers include, for example, carbonate ester (-OC(O)O-), succinoyl, phosphate ester (-O-(O)POH-O-), sulfonate ester, and combinations thereof. In some embodiments, the linker can be or include ethylene glycol (-CH2CH2-O-) or propylene glycol (-CH2-CH3CH-O-).

[0031] In some embodiments of the present disclosure, the linker or bond serves to connect the DOAB derivative of the present disclosure to a polymer, a functional peptide, a solid phase, a membrane, a lipid, a drug, etc. In some embodiments of the present disclosure, the polymer can be a BA-DMA copolymer or a DEA-DMA copolymer. In some embodiments of the present disclosure, the functional peptide can be insulin. In some embodiments of the present disclosure, the drug can be a protein or a small molecule compound.

[0032] In some embodiments of the present disclosure, preferably, the compounds represented by formula I above exclude compounds represented by formula V below. (V) (wherein R2 represents an H atom, a methyl group, an ethyl group, an i-propyl group, an n-butyl group, a t-butyl group, or a benzyl group.)

[0033] In some embodiments of the present disclosure, in the compound represented by the above formula I, R2 preferably excludes an H atom, a methyl group, an ethyl group, an i-propyl group, an n-butyl group, a t-butyl group, and a benzyl group.

[0034] In some aspects of the present disclosure, the compounds of the present disclosure are selected from the group consisting of: 2-(3-Fluorophenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3-(Trifluoromethyl)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-Cyanophenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-Nitrophenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-(trifluoromethyl)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3-(Trifluoromethyl)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-Tolyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-Methoxyphenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-(Dimethylamino)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3,5-Difluorophenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3,5-Di(trifluoromethyl)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane,5-Di(trifluoromethyl)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane), 2-(3-Fluoro-4-((2-acrylamidoethyl)carbamoyl)-phenyl)-6-methyl-[1,3,6,2]dioxazaborocane), 2-(3,4,5-Trifluorophenyl)-6-methyl-[1,3,6,2]dioxazaborocane), 2-(3-Pyridyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(2-Fluoro-3-pyridyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-Carboxy-3-pyridyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3-Pyridyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-Phenyl-4R,8R-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane, 2-Phenyl-4S,8S-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane, 2-Phenyl-rac-(4,8)-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane6,2]dioxazaborocane), 2-(3-Fluorophenyl)-rac-(4,8)-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane), 2-(3,5-Difluorophenyl)-rac-(4,8)-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane), 2-(3-Fluoro-4-((2-acrylamidoethyl)carbamoyl)-phenyl)-rac-(4,8)-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane, 2-Phenyl-4,4',6-trimethyl-[1,3,6,2]dioxazaborocane, The compound may be a compound selected from 2-phenyl-4,4',6,8,8'-pentamethyl-[1,3,6,2]dioxazaborocane, 2-phenyl-4,4',6,8,8'-pentamethyl-[1,3,6,2]dioxazaborocane, and 2-phenyl-5,5',6,7,8'-pentamethyl-[1,3,6,2]dioxazaborocane, or a derivative thereof.

[0035] Here, the derivative may be, for example, a compound in which a polymer, a functional peptide, a solid phase, a membrane, a lipid, a drug, or the like is linked to the compound of the present disclosure via a linker or bond. The derivative may be, for example, a smart insulin in which the compound of the present disclosure is incorporated into insulin (see, for example, Chen et al., PNAS 2021 Vol. 118 No. 30 e2103518118).

[0036] In some aspects of the present disclosure, the compound of the present disclosure is preferably not 2-(3-fluorophenyl)-6-methyl-1,3,6,2-dioxazaborocane or 2-(4-tolyl)-6-methyl-[1,3,6,2]dioxazaborocane.

[0037] In some aspects of the present disclosure, the compounds of the present disclosure are for linking to polymers, functional peptides, solid phases, membranes, lipids, drugs, and the like.

[0038] Some embodiments of the present disclosure include a compound of Formula II: (II) (wherein, each Y independently represents a substituted or unsubstituted —CH— or N atom; and R may be present in an amount of 1, 2, 3, 4, or 5, and each independently represents an H atom, an F atom, an electron-donating group (e.g., NMe, OH, OMe, Me, etc.), an electron-withdrawing group (e.g., CF, NO, CN, Br, CONH, etc.), a linker, or a bond) with a compound of the following formula (III): (III) (wherein, A 1a represents a H atom or a methyl group, and A 1b represents a H atom or a methyl group, and A 1c represents a H atom or a methyl group, and A 1d represents an H atom or a methyl group, where A 1a , A 1b , A 1c , A 1d At least one of A is a methyl group,2a represents a H atom or a methyl group, and A 2b represents a H atom or a methyl group, and A 2c represents a H atom or a methyl group, and A 2d represents an H atom or a methyl group, and R2 represents an H atom, a substituted or unsubstituted alkyl group, a linker, or a bond.

[0039] Here, the compound of formula (I) preferably excludes the compound represented by formula V. In the compound of formula (I), R2 preferably excludes an H atom, a methyl group, an ethyl group, an i-propyl group, an n-butyl group, a t-butyl group, and a benzyl group. In addition, the compound of formula (I) preferably is not 2-(3-fluorophenyl)-6-methyl-1,3,6,2-dioxazaborocane or 2-(4-tolyl)-6-methyl-[1,3,6,2]dioxazaborocane.

[0040] Some embodiments of the present disclosure also relate to a method for hydrolyzing a compound of formula I to form compounds of formula II and formula III, i.e., a method for producing compounds of formula II and formula III.

[0041] Here, the compound of formula I preferably excludes the compound represented by formula V. In the compound of formula I, R2 preferably excludes an H atom, a methyl group, an ethyl group, an i-propyl group, an n-butyl group, a t-butyl group, and a benzyl group. In addition, the compound of formula I is preferably not 2-(3-fluorophenyl)-6-methyl-1,3,6,2-dioxazaborocane or 2-(4-tolyl)-6-methyl-[1,3,6,2]dioxazaborocane.

[0042] Hydrolysis reaction of DOAB in aqueous solution at different pH values 1 The ratios of DOAB, BA, and DEA were calculated after equilibrium was reached, and the binding constant K a The stability was estimated from the viewpoint of K a The plots versus pH show the pK values ​​of the corresponding BA and DEA derivatives. a The theoretical maximum value calculated by the median of the values ​​(pH max ) (Fig. 2). max can be precisely shifted in a wide range by selecting different acidic BA and DEA derivatives.

[0043] Substituents at the boron, bicyclic ring, and adjacent nitrogen were investigated. For example, more acidic boronic acids were found to have pH values ​​much closer to the desired physiological pH of 7.4. max (Figure 2A), and fluorinated phenylboronic acid (R1 modification) can double the stability. Methylation of the bicyclic ring at positions 4 and 8 (A1 modification) results in high overall stability at all pH values ​​(Figure 2B). Indeed, pH max The stability at pH 7.4 was increased by up to 25-fold (Table 1). Alkylation of the nitrogen (R2 modification) further improved the stability at pH 7.4 by approximately 4-fold (Fig. 2C).

[0044]

[0045] Table 1 summarizes the binding constants of various modified DOAB adducts (I) in aqueous solution (HO / DO 9:1) at pH 7.4. Unless otherwise stated, R = H; R = Me; Y = CH; A / A = H. a 1 Coupling constants (K) estimated by H NMR a = [DOAB] / [BA] [DEA]); b Diastereomeric compound with meso form (1:1); c A diastereomeric compound that does not have a meso form.

[0046] To gain more insight into the temporal control of the equilibrium reaction, the reaction kinetics was analyzed in phosphate buffer (0.1 M) at pH 7.4. Interestingly, the dimethylated (A1 = Me / H) and tetramethylated DOAB (A1 = Me) exhibited almost identical binding constants, but the forward binding constant (k f ) and reverse (k r ) is approximately 1000 times slower (Fig. 3A). This results in an apparent binding constant, K a,t The range of bond strengths (K) over a given time interval was very wide (Fig. 3B), and a unique complex dissociation process was observed leading to equilibrium. For example, the tetramethylated compound exhibited similar bond strengths (K) to those of OB and HB within the first few hours of hydrolysis. a,1h ≒5×10 6 M -1 ), but becomes much weaker after a few days when the equilibrium state is established (K a,12d ≒130M -1 In contrast, the equilibrium state of the dimethylated compound was formed within 10 min and remained unchanged (Fig. 3B).

[0047] The glucose sensing ability of DOAB was investigated. For this purpose, different amounts of glucose were added to an aqueous solution of DOAB at pH 7.4. The ratio between DOAB, BA, and the formed glucose-BA complex was 11 The DOABs composed of more acidic boronic acids (e.g., R1 = 3-F, R1 = 4-CONH-Et-AAm) showed higher glucose response due to the stronger binding strength of the glucose-BA complex than the DOABs. glucose At normal blood glucose levels (c = 6-20 mM), DOAB begins to dissociate; however, the BA ratio does not increase, which means that the formed glucose-BA complex is caused by an exchange reaction (Fig. 4A). glucose At concentrations of 4-6 mM (R = 4-6 mM), DOAB remains unchanged, and the glucose-BA complex formed is primarily derived from free BA formed by equilibration of DOAB. In contrast, DOABs composed of less acidic boronic acids (e.g., R = H) exhibit lower binding strength of the glucose-BA complex compared to DOAB, resulting in a lower glucose response (Figure 4B).

[0048] We were interested in how the dissociation of DOAB functions in polymer networks. Therefore, we successfully functionalized DEA (A1 = Me, R1 = Et-AAm) and BA (R1 = 3-F,4-CONH-Et-AAm) with polymerizable groups and prepared copolymers (V) and (VI) using dimethylacrylamide (Figure 5A). Although the polymers are highly water-soluble, mixing polymer solutions containing DEA and BA resulted in gelation within minutes. The formed hydrogels were stable under neutral to slightly basic conditions, but the addition of HCl or NaOH solution partially decrosslinked the gel, resulting in liquefaction. This sol-gel transition could be repeated many times in each direction, demonstrating the reversibility of the crosslinked network (Figure 5B).

[0049] OB and HB are formed very rapidly at pH 7.4 (k f ≒10 2 M -1 S -1 ) and slow hydrolysis rate (kr ≈ 10 -4 s -1 ), which results in a very high binding constant (K a = k f / k r ≒10 6 M -1 Therefore, even at low concentrations (c = 100 μM), only 10% of the initial concentration is hydrolyzed. In contrast, tetramethylated DOAB (A1 = Me) exhibits a much slower hydrolysis rate (k r ≒10 -6 s -1 ), but the binding constant is much lower (K a ≒130M -1 As a result, at the same μM concentration, 99% of the starting concentration is hydrolyzed at a very slow rate. Therefore, tetramethylated DOAB may be a promising platform for long-term drug release systems.

[0050] Meta-fluorinated and dimethylated DOAB (R1 = 3-F, R1 = 4-CONH-Et-AAm; A1 = Me / H) can exhibit glucose-sensing capabilities under hyperglycemic conditions, making them particularly interesting for "smart" insulin applications.

[0051] The present invention provides a novel chemistry that is "clickable" and time-dependently "cleavable" in water, and has a very wide range of applications. This may provide an important platform for drug modification, protein conjugation including "smart insulin," DDS, self-healing materials, and so on.

[0052] It is to be understood that any feature, number, property, compound, chemical moiety or chemical group described in connection with a particular aspect, embodiment or example of the invention is applicable to other aspects, embodiments or examples described herein, unless inconsistent therewith.

[0053] The contents of all articles and documents related to this application, filed contemporaneously or previously hereto, and open to public inspection herewith, are hereby incorporated by reference.

[0054] All features disclosed in this specification (including any accompanying claims, abstract and drawings), and / or all steps of any method or process so disclosed, may be combined in any combination, except combinations in which at least some of such features and / or steps are mutually exclusive.

[0055] Each feature disclosed in this specification (including the accompanying claims, abstract, and drawings), unless expressly stated otherwise, may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.

[0056] The invention is not limited to the details of the foregoing embodiments, and extends to any novel feature, or any novel combination, or any method or process step, or any novel combination, so disclosed, disclosed in this specification (including the accompanying claims, abstract and drawings).

[0057] The scheme of the present invention will be explained below in conjunction with examples. Those skilled in the art will understand that the following examples are used only to illustrate the present invention and should not be construed as limiting the scope of the present invention. If no specific techniques or conditions are shown in the examples, the techniques or conditions described in the literature or product instructions in the field will be used. Reagents or equipment without manufacturer's markings are conventional products available on the market.

[0058] General Procedure (A) Phenyl / pyridylboronic acid derivatives (1.2 mmol) were suspended in acetone (4 mL). N-methyldiethanolamine derivatives (1.3 mmol) were then added, and the reaction mixture became clear. The mixture was stirred at room temperature for 20 hours, filtered, and the filtrate was concentrated to 1 mL using a nitrogen stream. This solution was stored in a freezer (-30 °C) for 20 hours. The formed crystals were removed by filtration and dried in vacuo. (If no crystals formed, diethyl ether or n-hexane (4 mL) was added, and the mixture was stored in the freezer for another 20 hours.)

[0059] General Procedure (B) Phenyl / pyridylboronic acid derivative (1.2 mmol) and sodium sulfate (10 mmol) were suspended in chloroform (4 mL). N-methyldiethanolamine derivative (1.8 mmol) was then added, and the reaction mixture was stirred at room temperature for 20 hours, filtered, and the filtrate was concentrated to 1 mL using a nitrogen stream. n-Hexane (4 mL) was added to the solution, and the mixture was stored in a freezer (-30 °C) for 20 hours. The formed crystals were removed by filtration and dried in vacuo.

[0060] Examples of DOAB derivatives that can be synthesized by the procedures of the present disclosure are shown below.

[0061]

[0062]

[0063] Examples of compounds of formula III above are also shown below.

[0064]

[0065] Example 1 2-(3-Fluorophenyl)-6-methyl-[1,3,6,2]dioxazaborocane

[0066] The title compound (81%, crystalline) was prepared from 3-fluorophenylboronic acid and N-methyldiethanolamine according to the general procedure (A). Diethyl ether was added for crystallization.

[0067] 1 H NMR (400 MHz, DMSO-d6) δ 7.33 - 7.13 (m, 3H), 6.96 (dddd, J = 9.3, 7.9, 2.9, 1.4 Hz, 1 H), 3.98 - 3.83 (m, 4H), 3.25 (ddd, J = 11.7, 5.4, 4.1 Hz, 2H), 2.97 (ddd, J = 11.7, 8.4, 6.6 Hz, 2H), 2.21 (s, 3H).

[0068] Example 2 2-(3-(Trifluoromethyl)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane

[0069] The title compound (99%, crystalline) was prepared from 3-(trifluoromethyl)phenylboronic acid and N-methyldiethanolamine according to the general procedure (A). Diethyl ether was added for crystallization.

[0070] 1 ​​H NMR (400 MHz, DMSO-d6) δ 7.76 (d, J = 5.6 Hz, 2H), 7.53 (d, J = 7.8 Hz, 1H), 7.44 (t, J = 7.7 Hz, 1H), 4.01 - 3.86 (m, 4H), 3.29 (ddd, J = 11.8, 5.4, 4.0 Hz, 2H), 3.01 (ddd, J = 11.7, 8.4, 6.7 Hz, 2H), 2.21 (s, 3H).

[0071] Example 3 2-(4-Cyanophenyl)-6-methyl-[1,3,6,2]dioxazaborocane

[0072] The title compound (91%, powder) was prepared from 4-cyanophenylboronic acid and N-methyldiethanolamine according to the general procedure (A). n-Hexane was added for crystallization.

[0073] 1 H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 8.2 Hz, 2H), 7.55 (d, J = 8.3 Hz, 2H), 4.27 - 4.02 (m, 4H), 3.22 (ddd, J = 11.6, 5.5, 4.1 Hz, 2H), 3.00 (ddd, J = 11.5, 8.4, 6.5 Hz, 2H), 2.30 (s, 3H).

[0074] Example 4 2-(4-Nitrophenyl)-6-methyl-[1,3,6,2]dioxazaborocane

[0075] The title compound (74%, crystalline) was prepared from 4-nitrophenylboronic acid and N-methyldiethanolamine according to the general procedure (A). Diethyl ether was added for crystallization.

[0076] 1 ​​H NMR (400 MHz, DMSO-d6) δ 8.07 (d, J = 8.6 Hz, 2H), 7.74 (d, J = 8.6 Hz, 2H), 4.02 - 3.87 (m, 4H), 3.30 (ddd, J = 11.7, 5.4, 4.1 Hz, 2H), 3.01 (ddd, J = 11.8, 8.4, 6.6 Hz, 2H), 2.22 (s, 3H).

[0077] Example 5 2-(4-(trifluoromethyl)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane

[0078] The title compound (34%, crystalline) was prepared from 4-(trifluoromethyl)phenylboronic acid and N-methyldiethanolamine according to the general procedure (A). Diethyl ether was added for crystallization.

[0079] 1 H NMR (400 MHz, DMSO-d6) δ 7.69 (d, J = 8.0 Hz, 2H), 7.54 (d, J = 7.9 Hz, 2H), 4.01 - 3.85 (m, 4H), 3.28 (ddd, J = 11.8, 5.4, 4.1 Hz, 2H), 2.99 (ddd, J = 11.8, 8.4, 6.6 Hz, 2H), 2.20 (s, 3H).

[0080] Example 6 2-(4-Tolyl)-6-methyl-[1,3,6,2]dioxazaborocane

[0081] The title compound (87%, crystalline) was prepared from 4-tolylboronic acid and N-methyldiethanolamine according to general procedure (A).

[0082] 1 ​​H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 7.9 Hz, 2H), 7.11 (d, J = 7.4 Hz, 2H), 4.25 - 4.07 (m, 4H), 3.16 (dt, J = 11.5, 4.8 Hz, 2H), 2.98 (ddd, J = 11.6, 8.3, 6.4 Hz, 2H), 2.32 (s, 3H), 2.31 (s, 3H).

[0083] Example 7 2-(4-Methoxyphenyl)-6-methyl-[1,3,6,2]dioxazaborocane

[0084] The title compound (34%, crystalline) was prepared from 4-methoxyphenylboronic acid and N-methyldiethanolamine according to the general procedure (A). Diethyl ether was added for crystallization.

[0085] 1 H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 8.5 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H), 4.26 - 4.03 (m, 4H), 3.80 (s, 3H), 3.16 (dt, J = 10.0, 5.1 Hz, 2H), 2.98 (dd, J = 12.4, 5.9 Hz, 2H), 2.31 (s, 3H).

[0086] Example 8 2-(4-(Dimethylamino)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane

[0087] The title compound (57%, crystalline) was prepared from 4-(dimethylamino)phenylboronic acid and N-methyldiethanolamine according to general procedure (A).

[0088] 1 ​​H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 8.6 Hz, 2H), 6.72 (d, J = 8.6 Hz, 2H), 4.26 - 4.01 (m, 4H), 3.23 - 3.08 (m, 2H), 3.03 - 2.89 (m, 2H), 2.93 (s, 6H), 2.32 (s, 3H).

[0089] Example 9 2-(3,5-Difluorophenyl)-6-methyl-[1,3,6,2]dioxazaborocane

[0090] The title compound (89%, crystalline) was prepared from 3,5-difluorophenylboronic acid and N-methyldiethanolamine according to the general procedure (A). Diethyl ether was added for crystallization.

[0091] 1 H NMR (400 MHz, DMSO-d6) δ 7.04 (ddd, J = 7.2, 2.5, 1.7 Hz, 2H), 6.95 (tt, J = 9.5, 2.5 Hz, 1H), 3.97 - 3.83 (m, 4H), 3.26 (ddd, J = 11.7, 5.4, ​​4.2 Hz, 2H), 3.00 (ddd, J = 11.7, 8.3, 6.6 Hz, 2H), 2.24 (s, 3H).

[0092] Example 10 2-(3,5-Di(trifluoromethyl)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane

[0093] The title compound (92%, crystalline) was prepared from 3,5-di(trifluoromethyl)phenylboronic acid and N-methyldiethanolamine according to the general procedure (A). Diethyl ether was added for crystallization.

[0094] 1 ​​H NMR (400 MHz, DMSO-d6) δ 8.04 (s, 2H), 7.88 (s, 1H), 4.04 - 3.87 (m, 4H), 3.38 - 3.28 (m, 2H), 3.08 (ddd, J = 11.8, 8.5, 6.9 Hz, 2H), 2.25 (s, 3H).

[0095] Example 11 2-(3-Fluoro-4-((2-acrylamidoethyl)carbamoyl)-phenyl)-6-methyl-[1,3,6,2]dioxazaborocane

[0096] The title compound (92%, powder) was prepared from 3-fluoro-4-((2-acrylamidoethyl)carbamoyl)-phenylboronic acid and N-methyldiethanolamine according to general procedure (A).

[0097] 1 H NMR (400 MHz, DMSO-d6) δ 8.25 - 8.15 (m, 2H), 7.52 (t, J = 7.4 Hz, 1H), 7.34 (d, J = 7.5 Hz, 1H), 7.23 (d, J = 11.9 Hz, 1H), 6.20 (dd, J = 17.1, 10.0 Hz, 1H), 6.08 (dd, J = 17.1, 2.3 Hz, 1H), 5.59 (dd, J = 9.9, 2.4 Hz, 1H), 3.98 - 3.84 (m, 4H), 3.40 - 3.22 (m, 6H), 2.99 (ddd, J = 11.7, 8.3, 6.6 Hz, 2H), 2.23 (s, 3H).

[0098] Example 12 2-(3,4,5-Trifluorophenyl)-6-methyl-[1,3,6,2]dioxazaborocane

[0099] ​The title compound (80%, crystalline) was prepared from 3,4,5-trifluorophenylboronic acid and N-methyldiethanolamine according to the general procedure (A).

[0100] 1 H NMR (400 MHz, DMSO-d6) δ 7.25 - 7.15 (m, 2H), 3.98 - 3.82 (m, 4H), 3.26 (ddd, J = 11.8, 5.4, 4.2 Hz, 2H), 3.00 (ddd, J = 11.7, 8.3, 6.7 Hz, 2H), 2.25 (s, 3H).

[0101] Example 13 2-(3-Pyridyl)-6-methyl-[1,3,6,2]dioxazaborocane

[0102] The title compound (20%, crystalline) was prepared from 3-pyridylboronic acid and N-methyldiethanolamine according to the general procedure (A). Diethyl ether was added for crystallization.

[0103] 1 H NMR (400 MHz, DMSO-d6) δ 8.60 (dd, J = 1.9, 1.0 Hz, 1H), 8.38 (dd, J = 4.8, 1.9 Hz, 1H), 7.78 (dt, J = 7.5, 1.9 Hz, 1H), 7.20 (ddd, J = 7.5, 4.8, 1.0 Hz, 1H), 3.99 - 3.84 (m, 4H), 3.27 (ddd, J = 11.7, 5.4, 4.1 Hz, 2H), 3.00 (ddd, J = 11.7, 8.4, 6.6 Hz, 2H), 2.24 (s, 3H).

[0104] Example 14 2-(2-Fluoro-3-pyridyl)-6-methyl-[1,3,6,2]dioxazaborocane

[0105] ​​The title compound (56%, crystalline) was prepared from 2-fluoro-3-pyridylboronic acid (1.2 mmol) and N-methyldiethanolamine (1.3 mmol) in toluene (30 mL). The reaction mixture was refluxed under Dean-Stark reflux for 1 hour, thereby removing most of the toluene (5 mL remaining). The mixture was then filtered, diethyl ether (10 mL) was added to the filtrate, and the mixture was stored in a freezer (-30 °C) for 20 hours. The formed crystals were removed by filtration and dried in vacuo.

[0106] 1 H NMR (400 MHz, DMSO-d6) δ 8.07 (ddd, J = 4.8, 2.2, 0.9 Hz, 1H), 8.00 (ddd, J = 9.2, 7.0, 2.2 Hz, 1H), 7.18 (ddd, J = 7.0, 4.8, 3.2 Hz, 1H), 3.97 - 3.81 (m, 4H), 3.29 (dt, J = 11.6, 5.1 Hz, 2H), 3.04 (ddd, J = 11.6, 8.0, 6.4 Hz, 2H), 2.42 (s, 3H).

[0107] Example 15 2-(4-Carboxy-3-pyridyl)-6-methyl-[1,3,6,2]dioxazaborocane

[0108] The title compound (67%, powder) was prepared from 4-carboxy-3-pyridylboronic acid and N-methyldiethanolamine according to general procedure (A).

[0109] 1 ​​H NMR (400 MHz, DMSO) δ 8.60 (dd, J = 1.9, 1.0 Hz, 1H), 8.38 (dd, J = 4.8, 1.9 Hz, 1H), 7.78 (dt, J = 7.5, 1.9 Hz, 1H), 7.20 (ddd, J = 7.5, 4.8, 1.0 Hz, 1H), 3.99 - 3.84 (m, 4H), 3.27 (ddd, J = 11.7, 5.4, 4.1 Hz, 2H), 3.00 (ddd, J = 11.7, 8.4, 6.6 Hz, 2H), 2.24 (s, 3H).

[0110] Example 16 2-(3-Pyridyl)-6-methyl-[1,3,6,2]dioxazaborocane

[0111] The title compound (49%, crystalline) was prepared from 4-pyridylboronic acid and N-methyldiethanolamine according to the general procedure (A). Diethyl ether was added for crystallization.

[0112] 1 H NMR (400 MHz, DMSO-d6) δ 8.39 (d, J = 5.7 Hz, 2H), 7.40 (d, J = 5.7 Hz, 2H), 3.99 - 3.84 (m, 4H), 3.28 (ddd, J = 11.8, 5.4, 4.2 Hz, 2H), 2.99 (ddd, J = 11.7, 8.3, 6.5 Hz, 2H), 2.23 (s, 3H).

[0113] Example 17 2-Phenyl-4R,8R-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane

[0114] The title compound (80%, crystalline) was prepared from phenylboronic acid and N-methyl 2R,2'R-diisopropanolamine according to general procedure (B).

[0115] 1 ​​H NMR (400 MHz, CDCl3) δ 7.61 (dd, J = 7.9, 1.7 Hz, 2H), 7.32 - 7.19 (m, 3H), 4.40 (dqd, J = 12.1, 6.0, 3.5 Hz, 1H), 4.29 (dqd, J = 10.1, 6.0, 4.0 Hz, 1H, DL), 3.06 (dd, J = 11.0, 3.5 Hz, 1H), 2.95 (dd, J = 11.4, 4.0 Hz, 1H), 2.71 (t, J = 11.0 Hz, 1H), 2.37 (t, J = 10.8 Hz, 1H), 2.26 (s, 3H), 1.38 (d, J = 6.0 Hz, 6H).

[0116] Example 18 2-Phenyl-4S,8S-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane

[0117] The title compound (83%, crystalline) was prepared from phenylboronic acid and N-methyl 2S,2'S-diisopropanolamine according to general procedure (B).

[0118] 1 H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 6.0 Hz, 2H), 7.30 - 7.17 (m, 3H), 4.36 (dqd, J = 12.0, 6.0, 3.5 Hz, 1H), 4.26 (ddd, J = 10.1, 6.0, 4.0 Hz, 1H), 3.03 (dd, J = 11.0, 3.5 Hz, 1H), 2.91 (dd, J = 11.5, 4.0 Hz, 1H), 2.67 (t, J = 11.1 Hz, 1H), 2.33 (t, J = 10.9 Hz, 1H), 2.22 (s, 3H), 1.36 (dd, J = 6.0, 1.6 Hz, 6H).

[0119] ​Example 19 2-Phenyl-rac-(4,8)-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane

[0120] The title compound (82%, crystalline) was prepared as a DL / meso mixture from phenylboronic acid and N-methyl-rac-diisopropanolamine according to the general procedure (A). Diethyl ether was added for crystallization.

[0121] 1 H NMR (400 MHz, CDCl3) δ 7.67 (dd, J = 7.7, 1.8 Hz, 2H, meso), 7.60 (dd, J = 8.0, 1.7 Hz, 2H, DL), 7.34 - 7.19 (m, 6H DL / meso), 4.51 (tt, J = 10.6, 5.8 Hz, 2H, meso), 4.39 (dqd, J = 12.0, 6.1, 3.6 Hz, 1H, DL), 4.29 (dqd, J = 10.1, 6.0, 4.0 Hz, 1H, DL), 3.20 (dd, J = 11.5, 4.7 Hz, 2H, meso), 3.05 (dd, J = 11.0, 3.6 Hz, 1H, DL), 2.94 (dd, J = 11.4, 4.0 Hz, 1H, DL), 2.70 (t, J = 11.0 Hz, 1H, DL), 2.53 (t, J = 10.7 Hz, 2H, meso), 2.36 (t, J = 10.9 Hz, 1H, DL), 2.31 (s, 3H, meso), 2.25 (s, 3H, DL), 1.38 (d, J = 6.0, 6H, DL), 1.35 (d, J = 5.9 Hz, 6H, meso). 11 B NMR (160 MHz, DMSO-d6) δ 10.93.

[0122] ​Example 20 2-(3-Fluorophenyl)-rac-(4,8)-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane

[0123] The title compound (85%, crystalline) was prepared as DL / meso from 3-fluorophenylboronic acid and N-methyl rac-diisopropanolamine according to general procedure (B).

[0124] 1 H NMR (400 MHz, CDCl3) δ 7.43 (dd, J = 7.3, 1.1 Hz, 1H, meso), 7.39 - 7.32 (m, 2H, DL / meso), 7.31 - 7.19 (m, 3H, DL / meso), 6.98 - 6.85 (m, 2H, DL / meso), 4.49 (ddd, J = 10.4, 6.0, 4.8 Hz, 2H, meso), 4.38 (dqd, J = 12.1, 6.0, 3.6 Hz, 1H, DL), 4.27 (dqd, J = 12.0, 6.0, 4.1 Hz, 1H, DL), 3.22 (dd, J = 11.6, 4.7 Hz, 2H, meso), 3.07 (dd, J = 11.0, 3.6 Hz, 1H, DL), 2.95 (dd, J = 11.5, 4.1 Hz, 1H, DL), 2.71 (t, J = 11.0 Hz, 1H, DL), 2.53 (t, J = 10.7 Hz, 2H), 2.35 (t, J = 10.9 Hz, 1H, DL), 2.32 (s, 3H, meso), 2.27 (s, 3H, DL), 1.37 (dd, J = 6.0, 1.2 Hz, 6H, DL), 1.34 (d, J = 5.9 Hz, 6H, meso). 11 B NMR (160 MHz, CDCl3) δ 11.18.

[0125] ​Example 21 2-(3,5-Difluorophenyl)-rac-(4,8)-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane

[0126] The title compound (85%, powder) was prepared as a DL / meso mixture from 3,5-difluorophenylboronic acid and N-methyl rac-diisopropanolamine according to general procedure (A).

[0127] 1 H NMR (400 MHz, DMSO-d6) δ 7.08 (dt, J = 7.1, 2.3 Hz, 2H, meso), 7.03 (dt, J = 7.1, 2.3 Hz, 2H, DL), 6.94 (tdd, J = 9.6, 3.8, 2.3 Hz, 2H, DL / meso), 4.27 (dp, J = 11.1, 5.6 Hz, 2H, meso), 4.14 (dtd, J = 10.5, 4.1, 2.1 Hz, 2H, DL), 3.40 (dd, J = 11.9, 4.7 Hz, 2H, meso), 3.20 (dd, J = 11.1, 3.6 Hz, 1H, DL), 3.07 (dd, J = 11.7, 4.1 Hz, 1H, DL), 2.67 (t, J = 11.2 Hz, 1H, DL), 2.53 (t, J = 11.1 Hz, 2H, meso), 2.38 (t, J = 10.9 Hz, 1H, DL), 2.25 (s, 3H, meso), 2.19 (s, 3H, DL), 1.21 (d, J = 5.1 Hz, 6H, DL), 1.18 (d, J = 6.0 Hz, 6H, meso). 11 B NMR (160 MHz, DMSO-d6) δ 9.93.

[0128] ​Example 22 2-(3-Fluoro-4-((2-acrylamidoethyl)carbamoyl)-phenyl)-rac-(4,8)-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane

[0129] The title compound (85%, powder) was prepared as a DL / meso mixture from 3-fluoro-4-((2-acrylamidoethyl)carbamoyl)-phenylboronic acid and N-methyllac-diisopropanolamine according to general procedure (A).

[0130] 1 ​H NMR (400 MHz, DMSO-d6) δ 8.25 - 8.15 (m, 4H, DL / meso), 7.52 (td, J = 7.5, 1.3 Hz, 2H, DL / meso), 7.38 (d, J = 7.6 Hz, 1H, meso), 7.33 (d, J = 7.6 Hz, 1H, DL), 7.26 (d, J = 11.9 Hz, 1H, meso), 7.21 (d, J = 11.9 Hz, 1H, DL), 6.20 (dd, J = 17.1, 10.0 Hz, 2H, DL / meso), 6.08 (dd, J = 17.1, 2.3 Hz, 2H, DL / meso), 5.59 (dd, J = 10.0, 2.4 Hz, 2H, DL / meso), 4.39 - 4.05 (m, 4H, DL / meso), 3.45 - 3.26 (m, 10H, DL / meso), 3.20 (dd, J = 10.6, 3.6 Hz, 1H, DL), 3.07 (dd, J = 11.6, 4.1 Hz, 1H, DL), 2.68 (t, J = 11.2 Hz, 1H, DL), 2.52 (t, J = 11.1 Hz, 2H, meso), 2.36 (t, J = 10.9 Hz, 1H, DL), 2.23 (s, 3H, meso), 2.17 (s, 3H, DL), 1.22 (d, J = 5.4 Hz, 6H, DL), 1.19 (d, J = 5.8 Hz, 6H, meso). 11 B NMR (160 MHz, DMSO-d6) δ 10.39.

[0131] Example 23 2-Phenyl-4,4',6-trimethyl-[1,3,6,2]dioxazaborocane

[0132] The title compound (75%, powder) was prepared from phenylboronic acid and N-methyl-N-(2,2-dimethyl-2-hydroxyethyl)ethanolamine according to general procedure (B).

[0133] 1 ​H NMR (400 MHz, CDCl3) δ 7.65 (dd, J = 7.7, 1.8 Hz, 2H), 7.32 - 7.20 (m, 3H), 4.26 - 4.10 (m, 2H), 3.17 - 3.06 (m, 2H), 3.02 - 2.87 (m, 2H), 2.41 (s, 3H), 1.48 (s, 3H), 1.48 (s, 3H).

[0134] Example 24 2-Phenyl-4,4',6,8,8'-pentamethyl-[1,3,6,2]dioxazaborocane

[0135] The title compound (45%, crystalline) was prepared from phenylboronic acid and N-methyl-N,N-di(2,2-dimethyl-2-hydroxyethyl)amine according to the general procedure (B).

[0136] 1 H NMR (400 MHz, CDCl3) δ 7.70 (dd, J = 8.1, 1.6 Hz, 2H), 7.31 - 7.17 (m, 3H), 3.33 (d, J = 12.1 Hz, 2H), 2.89 (d, J = 12.1 Hz, 2H), 2.57 (s, 3H), 1.55 (s, 6H), 1.46 (s, 6H). 11 B NMR (160 MHz, DMSO-d6) δ 12.22.

[0137] Example 25 2-Phenyl-4,4',6,7,8'-pentamethyl-[1,3,6,2]dioxazaborocane

[0138] ​The title compound (35%, crystalline) was prepared from phenylboronic acid (1.2 mmol), N-methyl-N,N-di(1,1-dimethyl-2-hydroxyethyl)amine (1.8 mmol), and sodium sulfate (10 mmol) in chloroform (2 mL). The reaction mixture was stirred at room temperature for 20 hours, filtered, and the filtrate was evaporated to dryness. The remaining solid was extracted with diethyl ether (5 x 10 mL). The filtrate was then concentrated to 2 mL, n-hexane (4 mL) was added, and the mixture was stored in a freezer (-30 °C) for 20 hours. The formed crystals were removed by filtration and dried in vacuo.

[0139] 1 H NMR (400 MHz, CDCl3) δ 7.67 (dd, J = 8.0, 1.6 Hz, 2H), 7.30 - 7.19 (m, 3H), 4.15 - 4.04 (m, 4H), 2.27 (s, 3H), 1.73 (s, 6H), 1.30 (s, 6H).

[0140] Example 26: pH-responsive (de)formation equilibrium reaction of DOAB in aqueous solution can be controlled in terms of binding constants

[0141] Method: 2-phenyl-[1,3,6,2]dioxazaborocane derivative (c = 20 mM) was dissolved in H2O / D2O (9:1). Then, 600 μL was taken and the pH was adjusted with diluted HCl or NaOH aqueous solution. A total of 7 to 10 samples with pH values ​​ranging from 6 to 11 were prepared. After 2 to 5 hours, the samples were 1 The concentrations of boronic acid (BA), diethanolamine (DEA), and [1,3,6,2]dioxazaborocane (DOAB) derivatives were analyzed by H NMR and estimated by ratio. The samples were reanalyzed after 1 day to confirm that equilibrium had been reached and that the pH value had not changed. The binding constant (K a / M -1 ) was calculated using Equation 1.

[0142] (1)

[0143] K a In the plot vs. pH, the pK of the corresponding BA and DEA derivatives a The theoretical maximum value calculated from the median value (pH​max ) was shown to follow a bell-shaped relationship (fitted to a Gaussian function) (Equation 2).

[0144] (2)

[0145] Figure 6A shows a schematic diagram of the R1-modified DOABs studied. Figure 6B shows the binding constants K a The relationship between the pH and the concentration is shown.

[0146] Figure 7A shows a schematic diagram of the A1-modified DOAB studied. Figure 7B shows the binding constant K a The relationship between the pH and the concentration is shown.

[0147] Figure 8A shows a schematic diagram of the R2-modified DOABs studied. Figure 8B shows the binding constants K a The relationship between the pH and the concentration is shown.

[0148] Example 27: The equilibrium reaction of (de)production of DOAB in aqueous solution can be controlled in terms of rate constants.

[0149] Method: [1,3,6,2]dioxazaborocane derivative (c0 = 5 mM) was dissolved in phosphate buffer (0.1 M, pH 7.4, H2O / D2O = 9:1). Immediately after dissolving, 600 μL of the solution was added to an NMR tube and stirred until equilibrium was reached. 1 H NMR spectra were recorded. From the ratio of DEA to DOAB, the concentration of DOAB at different times was estimated and the rate constant was calculated.

[0150] The reversible equilibrium reactions of BA, DEA, and DOAB in aqueous solution are second-order reactions (k f / M -1 s -1 - forward rate constant) and first-order reverse reaction (k r / s -1 -inverse rate constant).

[0151]

[0152] The following conditions apply at all times: c0 is the initial concentration of DOAB. [DOAB] = c [BA] = [DEA] = c0 - c

[0153] The rate law of this equilibrium reaction can be described by Equations 3 and 4.

[0154] (3)

[0155] (4)

[0156] The integral in Equation 3 was derived in a similar manner to Dirkson et al. (A. Dirksen, S. Dirksen, TM Hackeng, PE Dawson, J. Am. Chem. Soc. 2006, 128, 15602-15603.) The integral rate law (Equations 5, 6, and 7) describes both the formation and hydrolysis of DOAB. Therefore, fitting the data with this kinetic model yielded k f and k r could be calculated simultaneously.

[0157] (5)

[0158] (6)

[0159] (7)

[0160] Figure 9A shows a schematic diagram of the A1-modified DOAB studied. Figure 9B shows the DOAB concentration at different time intervals. The dashed lines are the fitting results of the kinetic model.

[0161] Example 28 DOAB can interact with glucose via a dissociative mechanism

[0162] We investigated whether DOAB can interact with glucose by varying the amount of interaction. The binding constant (K a,glucose ) is the binding constant of DOAB (K a,DOAB ) were found to exhibit high glucose responsiveness (see FIG. 10).

[0163] Figure 10A is a schematic diagram showing the possible interactions of DOAB with glucose through binding or dissociation mechanisms. Figure 10B shows the interaction of glucose-BA (K a,glucose ) and DOAB(k a,DOAB ) shows the equation for the binding constant of the equilibrium reaction.

[0164] Methods: [1,3,6,2] Dioxazaborocane derivative (c = 20 mM) was dissolved in H2O / D2O (9:1) and the pH value was adjusted to 7.4 with diluted HCl (0.1 M). This solution was divided into two aliquots, and D-glucose (c = 80 mM) was added to one of them. Then, mixtures of different glucose concentrations (c = 0 to 80 mM) were prepared using these two solutions. 600 μL of each aliquot was taken and placed in an NMR tube. 11 B NMR spectra were recorded. Peaks were assigned to DOAB, BA, and glucose-BA, and their ratios were calculated by integration (Figures 11 and 12). Where necessary, overlapping peaks were deconvoluted prior to analysis according to Matsumoto et al. [1].

[0165] Figure 11A shows high glucose response (K a,DOAB ≦K a,glucose Figure 11B shows a schematic diagram of the investigated R1 and A1 modified DOABs, showing the effect of varying glucose concentrations. 11 Figure 11C shows the ratio of DOAB, glucose-BA, and BA.

[0166] Figure 12A shows the low glucose response (K a,DOAB >K a,glucose Figure 12B shows a schematic diagram of the A1-modified DOAB showing the effect of varying glucose concentrations. 11 Figure 12C shows the ratio of DOAB, Glucose-BA, and BA.

[0167] Example 29 Incorporation into polymers and other structures

[0168] FIG. 13 shows a schematic diagram of the monomer and polymer.

[0169] Monomer 1 N-(2-acrylamidoethyl)N,N-di(2,2-dimethyl-2-hydroxyethyl)amine

[0170] N-(2-aminoethyl)acrylamide hydrochloride [2] (2.11 g, 14 mmol) was dissolved in HO (7 mL), and the pH of the solution was adjusted to 14 with 2 M NaOH solution. The mixture was degassed by bubbling argon through it and cooled to 0 °C in an ice bath. Isobutylene oxide (2.65 mL, 29 mmol) was then slowly added, and the reaction mixture was stirred at room temperature. After 1 day, additional isobutylene oxide (0.43 mL, 4 mmol) was added. After 2 days, the reaction mixture was extracted with chloroform (5 × 30 mL), and the combined extracts were dried over MgSO, filtered, and the filtrate was evaporated to dryness. The residue was purified by flash column chromatography (CHCl / MeOH = 9:1) to give the title compound (50%, powder).

[0171] Polymer 1: Poly(N,N-dimethylacrylamide-co(N-(2-acrylamidoethyl)N,N-di(2,2-dimethyl-2-hydroxyethyl)amine))

[0172] The title compound (90%) was prepared from N,N-dimethylacrylamide (1070 mg, 10.8 mmol), N-(2-acrylamidoethyl)N,N-di(2,2-dimethyl-2-hydroxyethyl)amine (310 mg, 1.2 mmol), and AIBN (4.9 mg, 0.03 mmol) in MeOH (4 mL). The solution was degassed by bubbling argon through it and then heated to 60 °C for 20 h. The reaction mixture was then dialyzed, and the solution was lyophilized.

[0173] GPC (10mM LiCl in DMF, PEG standard) Mn=22800g / mol; PDI=2.2 1 H NMR (400 MHz, D2O) δ 3.34 - 2.24 (br), 1.90 - 1.28 (br), 1.21 (br).

[0174] Monomer 2 3-Fluoro-4-((2-acrylamidoethyl)carbamoyl)-phenylboronic acid

[0175] The title compound was prepared according to the method described in the literature [3].

[0176] Polymer 2: Poly(N,N-dimethylacrylamide-co-(3-fluoro-4-((2-acrylamidoethyl)carbamoyl)-phenylboronic acid))

[0177] The title compound (83%) was prepared from N,N-dimethylacrylamide (1070 mg, 10.8 mmol), 3-fluoro-4-((2-acrylamidoethyl)carbamoyl)-phenylboronic acid (336 mg, 1.2 mmol), and AIBN (4.9 mg, 0.03 mmol) in MeOH (4 mL). The solution was degassed by bubbling argon through it and then heated to 60 °C for 20 h. The reaction mixture was then dialyzed, and the solution was lyophilized.

[0178] 1 H NMR (400 MHz, D2O) δ 7.91 - 7.01 (br), 3.75 - 3.28 (br), 3.25 - 2.31 (br), 1.95 - 1.01 (br).

[0179] FIG. 14 shows a schematic diagram of cross-linked polymer formation and partial hydrolysis with acid or base.

[0180] Methods: Solutions of polymer 1 and polymer 2 (c = 10 w / w%) were prepared in HO. 400 μL of polymer 1 solution was taken and 200 μL of polymer 2 solution was added (Figure 14). Phenol red (1 mg) was added as a pH indicator and for visualization. The mixture was then vortexed for 3 seconds every 5 minutes, and visible gelation occurred after 15–20 minutes. After 1 day, the crosslinked polymer became more rigid and formed a solid-like material. Mixing the polymer solutions resulted in a neutral to slightly alkaline solution (pH 7–8), close to the pH value of 7.8, where the DOAB unit of this series is most stable. Hydrolysis and desorption occur at both higher and lower pHs. Therefore, the addition of dilute HCl or NaOH solution (5 M, 5–10 μL) resulted in liquefaction within 10 hours, depending on the gel's hardness (Figure 15A). Returning the pH to its original value allowed the gel to reform within 30 minutes.

[0181] The gelation process was monitored by NMR under the same conditions in a separate experiment. An NMR tube was filled with the two polymer solutions.​11 B NMR was measured initially and after 4 and 48 hours. The formation of DOAB units was indicated by a new signal appearing around 10 ppm (FIG. 15B).

[0182] Figure 15A shows the dynamic behavior of cross-linked polymers at different pH values, visualized macroscopically by the sol-gel transition. Figure 15B shows the dynamic behavior of cross-linked polymers at different time intervals after mixing the polymer solutions. 11 The results of B NMR are shown.

[0183] References [1] A. Matsumoto, AJ Stephenson-Brown, T. Khan, T. Miyazawa, H. Cabral, K. Kataoka, Y. Miyahara, Chem. Sci. 2017, 8, 6165-6170. [2] Y. Ma, L.-YL Yung, Anal. Chem. 2014, 86, 2429-2435. [3] A. Matsumoto, T. Ishii, J. Nishida, H. Matsumoto, K. Kataoka, Y. Miyahara, Angew. Chem. Int. Ed. 2012, 51, 2124-2128.

Claims

1. Formula I: (I) (wherein, A 1a represents a H atom or a methyl group, A 1b represents a H atom or a methyl group, A 1c represents a H atom or a methyl group, A 1d represents an H atom or a methyl group, where A 1a , A 1b , A 1c , A 1d At least one of A is a methyl group; 2a represents a H atom or a methyl group, A 2b represents a H atom or a methyl group, A 2c represents a H atom or a methyl group, A 2d represents an H atom or a methyl group, each Y independently represents a substituted or unsubstituted -CH- or N atom, R1 may be present in an amount of 1, 2, 3, 4 or 5, each independently representing an H atom, an F atom, an electron donating group, an electron withdrawing group, a linker or a bond, and R2 represents an H atom, a substituted or unsubstituted alkyl group, a linker or a bond.

2. The compound of claim 1, wherein the electron donating group is selected from the group consisting of NMe2, OH, OMe, and Me.

3. The compound of claim 1, wherein the electron-withdrawing group is selected from the group consisting of CF3, NO2, CN, Br, and CONH.

4. The following group: 2-(3-fluorophenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3-(trifluoromethyl)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-cyanophenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-nitrophenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-(trifluoromethyl)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-tolyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-methoxyphenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-(dimethylamino)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3,5-difluorophenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3,5-di(trifluoromethyl)phenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3-fluoro-4-((2-acrylamidoethyl)carbamoyl)-phenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3,4,5-trifluorophenyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3-pyridyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(2-fluoro-3-pyridyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-Carboxy-3-pyridyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-(4-pyridyl)-6-methyl-[1,3,6,2]dioxazaborocane, 2-phenyl-4R,8R-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane, 2-phenyl-4S,8S-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane, 2-phenyl-rac-(4,8)-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3-fluorophenyl)-rac-(4,8)-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3,5-difluorophenyl)-rac-(4,8)-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane, 2-(3-fluoro-4-((2-acrylamidoethyl)carbamoyl)-phenyl)-rac-(4,8)-dimethyl-6-methyl-[1,3,6,2]dioxazaborocane, 2-phenyl-4,4',6-trimethyl-[1,3,6,2]dioxazaborocane, 2-phenyl-4,4',6,8,8'-pentamethyl-[1,3,6,2]dioxazaborocane, and 2-phenyl-4,4',6,7,8'-pentamethyl-[1,3,6,2]dioxazaborocane, or a derivative thereof.

5. The compound of claim 1, wherein any one of Y is linked to a polymer, a functional peptide, or a drug.

6. The compound according to claim 5, wherein the polymer is a BA-DMA copolymer.

7. The compound according to claim 5, wherein the functional peptide is insulin.

8. The compound of claim 5, wherein the drug is a protein.

9. The compound of claim 1, wherein R2 is linked to a polymer.

10. The compound according to claim 9, wherein the polymer is a DEA-DMA copolymer.

11. A method for adjusting the binding / dissociation reaction shown below, comprising: (In the formula, A 1a represents a H atom or a methyl group, A 1b represents a H atom or a methyl group, A 1c represents a H atom or a methyl group, A 1d represents an H atom or a methyl group, where A 1a , A 1b , A 1c , A 1d At least one of A is a methyl group; 2a represents a H atom or a methyl group, A 2b represents a H atom or a methyl group, A 2c represents a H atom or a methyl group, A 2d represents an H atom or a methyl group, each Y independently represents a substituted or unsubstituted -CH- or N atom, R1 may be present in an amount of 1, 2, 3, 4 or 5, each independently represents an H atom, an F atom, an electron donating group, an electron withdrawing group, a linker or a bond, and R2 represents an H atom, a substituted or unsubstituted alkyl group, a linker or a bond.) A method comprising changing the pH of a solution.

12. The method of claim 11, wherein the dissociation reaction is accelerated by increasing or decreasing the pH away from the optimum pH for binding.

Citation Information

Patent Citations

  • Gasoline containing dialkanolamine boronic acid bis-esters

    US3021206A

  • Boron compounds as stabilizers in photothermographic materials

    WO2006071586A1